<?xml version="1.0" encoding="UTF-8"?>
<p id="p0210">The human convalescent plasma from the recovered patients can be another option for COVID-19 management [
 <xref rid="bb0790" ref-type="bibr">158</xref>,
 <xref rid="bb0795" ref-type="bibr">159</xref>]. The passive immunoglobulin-containing plasma can provide immediate immunity to the susceptible individual. There is a long history of this passive antibody treatment in various infective diseases beyond the era of antimicrobial development [
 <xref rid="bb0800" ref-type="bibr">160</xref>,
 <xref rid="bb0805" ref-type="bibr">161</xref>]. A meta-analysis suggested the beneficial role of early administration of convalescent plasma on the mortality reduction during influenza epidermic in 1918 [
 <xref rid="bb0795" ref-type="bibr">159</xref>]. There is no report of serious adverse effects of the treatment up to now. The convalescent plasma from the patients who have recovered from the viral infection is thus another rational option for COVID-19 management [
 <xref rid="bb0800" ref-type="bibr">160</xref>,
 <xref rid="bb0805" ref-type="bibr">161</xref>].
</p>
